Geldanamycin inhibits migration of glioma cells in vitro: A potential role for hypoxia‐inducible factor (HIF‐1α) in glioma cell invasion
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Focal adhesion kinase (FAK) and hypoxia‐inducible factor (HIF‐1α) are both up‐regulated in glioblastoma multiforme (GBMs), particularly in invasive zones. Because FAK may play an important role in the invasion of glioma cells into the surrounding brain, we sought an agent that causes down‐regulation of FAK phosphorylation as a potential inhibitor of brain tumor invasion and growth. Geldanamycin (GA), a benzoquinone ansamycin antibiotic, binds to heat shock protein 90 (Hsp90) and interferes with its function. GA inhibits the proliferation of various non‐glial cells and has anti‐tumor activity. Moreover, GA blocks HIF‐regulated transcription of VEGF and inhibits the VEGF‐induced phosphorylation of FAK and migration of endothelial cells. Here, we tested the effect of GA on glioma cell migration in vitro and its potential to down‐regulate HIF‐1α induction. Our results demonstrate that GA (i) decreases U87MG, LN229, and U251MG glioma cell migration; (ii) reduces cell migration independent of p53 and PTEN status; (iii) prevents migration at non‐toxic concentrations; (iv) reduces phosphorylation of FAK; and (v) inhibits cobalt chloride (CoCl 2)‐mediated induction of HIF‐1α in glioma cells. To the best of our knowledge, this is the first report showing that GA can inhibit phosphorylation of FAK concomitant with a decrease in cellular migration. One of the most clinically relevant aspects of this study is that GA interferes with the induction of HIF‐1α that has been linked with glioma cell migration and angiogenesis. Given the fact that GA is a small lipophilic molecule capable of penetrating the blood brain barrier together with the data presented here provide a strong rationale for its use or its analogues in the treatment of highly invasive GBMs. J. Cell. Physiol. 196: 394–402, 2003. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300 · cited 1×
“For instance, p53 status is known to modulate the response of tumor cells to hypoxia (Graeber et al., 1996).”
BackgroundWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Burridge, K., Turner, C. E., & Romer, L. H. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.4.893 · Cited by 1,387
Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN
Tamura, M., Gu, J., Matsumoto, K., Aota, S.-I., Parsons, R., & Yamada, K. M. (1998) · Science · doi:10.1126/science.280.5369.1614 · Cited by 1,215
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967 · cited 2×
“Since p53 and PTEN mutations can affect HIF-1a and FAK expression in response to hypoxia (Ravi et al., 2000; Zundel et al., 2000), we selected glioma cell lines (U251MG, U87MG, and LN229) that differed in p53 and PTEN status.”
BackgroundLoss of PTEN facilitates HIF-1-mediated gene expression
Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., et al. (2000) · Genes & Development · doi:10.1101/gad.14.4.391 · Cited by 840
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204733200 · Cited by 663 · cited 9×
“For example, GA blocks tyrosine phosphorylation of FAK and inhibits migration of VEGF-treated endothelial cells (Rousseau et al., 2000).”
BackgroundInfluentialGradin, K., McGuire, J., Wenger, R. H., Kvietikova, I., Whitelaw, M. L., Toftgård, R., Tora, L., Gassmann, M., & Poellinger, L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5221 · Cited by 470
Coumailleau, P., Poellinger, L., Gustafsson, J.-Å., & Whitelaw, M. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.42.25291 · Cited by 172 · cited 1×
“Similarly, hypoxia has been shown to increase the invasive capacity of cancer cells (Cuvier et al., 1997) by stimulating the expression of plasminogen activator inhibitor-1 (PAI-1) (Fitzpatrick and Graham, 1998) and of the urokinase receptor (Graham et al., 1998; Graham et al., 1999).”
Background
Cited by
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion
Bellail, A. C., Hunter, S. B., Brat, D. J., Tan, C., & Van Meir, E. G. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.01.013 · Cited by 526
Brat, D. J., Castellano-Sanchez, A. A., Hunter, S. B., Pecot, M., Cohen, C., Hammond, E. H., Devi, S. N., Kaur, B., & Van Meir, E. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2073 · Cited by 485
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape
Wu, Q., You, L., Nepovimova, E., Heger, Z., Wu, W., Kuca, K., & Adam, V. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01292-6 · Cited by 485
Lactate: mirror and motor of tumor malignancy
Walenta, S., & Mueller-Klieser, W. F. (2004) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2004.04.004 · Cited by 428
Neckers, L., & Ivy, S. P. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200311000-00003 · Cited by 400
Heat shock protein 90: The cancer chaperone
Neckers, L. (2007) · Journal of Biosciences · doi:10.1007/s12038-007-0051-y · Cited by 365
Jensen, R. L. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9827-2 · Cited by 287
Ambruosi, A., Khalansky, A. S., Yamamoto, H., Gelperina, S. E., Begley, D. J., & Kreuter, J. (2006) · Journal of Drug Targeting · doi:10.1080/10611860600636135 · Cited by 119
Zhang, J. Z., Bryce, N. S., Siegele, R., Carter, E. A., Paterson, D., de Jonge, M. D., Howard, D. L., Ryan, C. G., & Hambley, T. W. (2012) · Integrative Biology · doi:10.1039/c2ib20121f · Cited by 37
Metadata
- Authors
- Zagzag, D., Nomura, M., Friedlander, D. R., Blanco, C., Gagner, J., Nomura, N., & Newcomb, E. W.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2003-06-10
- Volume
- 196
- Issue
- 2
- Pages
- 394-402
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2168267246
- Cited by
- 109
- References
- 9
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.